Psoriasis

What is Psoriasis?

Psoriasis is a chronic autoimmune skin condition that causes the rapid buildup of skin cells, resulting in thick, scaly patches on the skin’s surface. This inflammatory disease affects approximately 2-3% of the global population, making it one of the most common chronic skin conditions worldwide. Psoriasis can develop at any age but typically appears between ages 15-35 or 50-60, affecting men and women equally. While primarily a skin condition, psoriasis is now recognized as a systemic inflammatory disease that can impact joints, cardiovascular health, and overall quality of life.

Key statistics

Statistic	Value
Global prevalence	2-3% of population (125+ million people)
Peak age of onset	15-35 years (type 1) or 50-60 years (type 2)
Genetic component	40% concordance in identical twins
Psoriatic arthritis development	30% of psoriasis patients

Symptoms

Common symptoms include: Red, inflamed patches of skin, thick silvery scales, dry cracked skin, itching and burning sensations, thickened or ridged nails, and joint pain or stiffness.

The hallmark symptom of psoriasis is the development of well-demarcated, raised, red patches (plaques) covered with silvery-white scales. These lesions most commonly appear on the elbows, knees, scalp, and lower back, though they can occur anywhere on the body. Patients frequently experience intense itching, burning, or soreness in affected areas. The skin may crack and bleed, particularly during flare-ups.

Nail changes occur in approximately 50% of patients, including pitting, discoloration, thickening, and separation from the nail bed. Some individuals develop psoriatic arthritis, characterized by joint pain, stiffness, and swelling, particularly in the fingers, toes, and spine. Scalp psoriasis can range from mild scaling to thick, crusted plaques that extend beyond the hairline. In severe cases, psoriasis can cover large areas of the body, leading to significant physical discomfort and emotional distress.

Causes and risk factors

Psoriasis is an autoimmune condition caused by an overactive immune system that mistakenly attacks healthy skin cells, accelerating the skin cell production cycle from 28 days to 3-7 days. This rapid turnover prevents proper cell maturation and leads to the characteristic scaling and inflammation.

Genetic factors play a significant role, with over 60 genetic variants identified as contributing to psoriasis risk. Family history is a strong predictor, with children having a 10% chance if one parent has psoriasis and 50% if both parents are affected. Environmental triggers that can initiate or worsen psoriasis include infections (particularly streptococcal throat infections), skin injuries (cuts, scrapes, sunburn), stress, certain medications (lithium, beta-blockers, antimalarials), smoking, excessive alcohol consumption, and obesity. Weather changes, particularly cold and dry conditions, can also trigger flare-ups.

Prevention

Currently, there is no known way to prevent psoriasis due to its genetic component. However, individuals with a family history can reduce their risk of developing the condition or experiencing flare-ups through lifestyle modifications. Maintaining a healthy weight, avoiding smoking and excessive alcohol consumption, managing stress through relaxation techniques or counseling, and protecting skin from injury can help. Regular moisturizing, avoiding harsh soaps and detergents, and limiting exposure to known triggers may prevent flare-ups in susceptible individuals. Early identification of family history allows for prompt recognition and treatment of symptoms when they develop.

Complications

Without proper treatment, psoriasis can lead to significant physical and psychological complications. Psoriatic arthritis develops in approximately 30% of patients and can cause permanent joint damage if left untreated. The chronic inflammation associated with psoriasis increases the risk of cardiovascular disease, including heart attack and stroke, with patients having a 25% higher risk of major cardiac events.

Mental health complications are common, with depression and anxiety affecting up to 60% of patients due to the visible nature of the condition and its impact on quality of life. Other potential complications include metabolic syndrome, diabetes, inflammatory bowel disease, and certain cancers. Severe psoriasis can lead to erythrodermic psoriasis, a life-threatening condition where inflammation covers most of the body, causing severe itching, pain, and potential temperature regulation problems.

Diagnosis

Psoriasis is primarily diagnosed through clinical examination by a dermatologist or trained healthcare provider. The characteristic appearance of plaques, their distribution pattern, and associated symptoms usually provide sufficient information for diagnosis. The Koebner phenomenon (development of psoriatic lesions at sites of skin trauma) and Auspitz sign (pinpoint bleeding when scales are removed) are classic diagnostic features.

In uncertain cases, a skin biopsy may be performed to confirm the diagnosis and rule out other conditions. Blood tests are not routinely needed for psoriasis diagnosis but may be ordered to assess for associated conditions or to monitor treatment effects. The Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) are standardized tools used to assess disease severity and treatment response. For patients with joint symptoms, imaging studies such as X-rays, MRI, or ultrasound may be necessary to evaluate for psoriatic arthritis.

Treatment

Psoriasis treatment follows a stepped approach based on disease severity and patient factors. Topical treatments are first-line therapy for mild to moderate psoriasis and include corticosteroids, calcipotriene (vitamin D analogues), tazarotene (topical retinoids), and tacrolimus or pimecrolimus (calcineurin inhibitors).

Phototherapy, including narrowband UV-B and PUVA (psoralen plus UV-A), is effective for moderate to severe psoriasis. Systemic treatments for severe disease include traditional therapies like methotrexate, cyclosporine, and acitretin.

Biologic medications have revolutionized psoriasis treatment, targeting specific immune pathways. TNF-alpha inhibitors include adalimumab, etanercept, and infliximab. IL-17 inhibitors include secukinumab, ixekizumab, and brodalumab. IL-23 inhibitors include ustekinumab, guselkumab, and tildrakizumab. Newer oral treatments include apremilast and JAK inhibitors like deucravacitinib.

Prognosis

Psoriasis is a chronic condition with a variable course characterized by periods of improvement and flare-ups. With modern treatments, most patients can achieve significant improvement in their symptoms and quality of life. Approximately 75% of patients treated with biologics achieve at least 75% improvement in their PASI score (PASI 75 response).

Life expectancy may be slightly reduced, primarily due to increased cardiovascular risk, with studies suggesting a 3-4 year reduction in severe cases. However, this risk can be significantly mitigated through proper management of psoriasis and associated comorbidities. The condition’s impact on quality of life varies widely, with some patients experiencing minimal disruption while others face significant physical and emotional challenges. Early diagnosis and appropriate treatment lead to better long-term outcomes and reduced risk of complications.

Quality of life

Living with psoriasis requires ongoing self-management and lifestyle adaptations. Daily skincare routines should include gentle cleansing with mild, fragrance-free soaps and regular moisturizing, particularly after bathing. Stress management techniques such as meditation, yoga, or counseling can help reduce flare-ups and improve overall well-being.

Dietary modifications may benefit some patients, with anti-inflammatory diets rich in omega-3 fatty acids, fruits, and vegetables showing promise. Weight management is crucial, as obesity can worsen symptoms and reduce treatment effectiveness. Regular exercise, adapted to avoid excessive sweating or skin irritation, supports both physical and mental health. Sun exposure in moderation can be beneficial, but patients should protect against sunburn.

Social support is vital, as the visible nature of psoriasis can lead to self-consciousness and social isolation. Joining support groups, either in-person or online, can provide valuable emotional support and practical advice. Workplace accommodations may be necessary during flare-ups, and open communication with employers about the condition can help reduce stress and discrimination.

Pregnancy and fertility

Psoriasis does not directly affect fertility, but some treatments can impact reproductive health. The condition may improve during pregnancy due to hormonal changes, with approximately 40-60% of women experiencing improvement, particularly during the second and third trimesters. However, postpartum flares are common.

Many psoriasis medications are not safe during pregnancy. Methotrexate and acitretin are teratogenic and must be discontinued before conception. Some biologics like adalimumab and etanercept may be continued during pregnancy under close medical supervision. Topical treatments and certain phototherapy options remain safe alternatives. Women with psoriasis should discuss family planning with their healthcare providers to develop safe treatment plans during pregnancy and breastfeeding.

Children

Pediatric psoriasis affects approximately 1% of children and often presents differently than adult disease. Guttate psoriasis, characterized by small, drop-like lesions, is more common in children and frequently follows streptococcal infections. Diaper area involvement in infants and facial involvement in children are more frequent than in adults.

Treatment approaches in children emphasize safety and age-appropriate formulations. Topical therapies remain first-line, with careful attention to potency and application sites to avoid side effects. Phototherapy can be effective in older children, while systemic treatments are reserved for severe cases. School accommodations may be necessary to address physical limitations and potential bullying. Transition to adult care should be planned carefully during adolescence to ensure continuity of treatment and emotional support.

When to see a doctor

Immediate medical attention is required if patients develop signs of erythrodermic psoriasis, including widespread redness covering most of the body, severe itching or pain, fever, or chills. Secondary bacterial infections, indicated by increased warmth, pus, red streaking, or fever, also require urgent care.

Routine dermatological consultation is recommended for new skin lesions suggestive of psoriasis, worsening of existing psoriasis despite treatment, or development of joint pain or stiffness. Patients should also seek care if their condition significantly impacts quality of life, work, or relationships. Regular follow-up appointments are essential for monitoring treatment response, managing side effects, and screening for associated conditions such as cardiovascular disease and depression.

Regional context

Limited specific data exists regarding psoriasis prevalence in the Caucasus region, though European studies suggest prevalence rates consistent with global averages of 2-3%. The region’s diverse genetic background and varying environmental factors may influence disease presentation and severity. Access to biologic therapies may be limited in some areas, requiring reliance on traditional systemic treatments and phototherapy. GMJ welcomes contributions from regional researchers to build the evidence base for psoriasis in the Caucasus, particularly regarding genetic variants, environmental triggers, and treatment accessibility in Georgia, Armenia, and Azerbaijan.

Research and clinical trials

Current psoriasis research focuses on developing more targeted therapies with improved safety profiles. Oral treatments targeting specific inflammatory pathways, including JAK inhibitors and TYK2 inhibitors, are showing promising results. Personalized medicine approaches aim to match patients with optimal treatments based on genetic profiles and biomarkers.

Microbiome research is exploring the role of gut and skin bacteria in psoriasis development and treatment. Gene therapy and stem cell treatments are in early development stages. Patients interested in clinical trials can search ClinicalTrials.gov for current studies. Recent breakthroughs include IL-23p19 inhibitors achieving unprecedented clearance rates and the development of topical JAK inhibitors for localized treatment.

Frequently asked questions

Is psoriasis contagious?

No, psoriasis is not contagious. It is an autoimmune condition that cannot be transmitted through physical contact, sharing personal items, or any other means of person-to-person contact.

Will my psoriasis ever go away completely?

While psoriasis is a chronic condition, many patients can achieve complete or near-complete clearance with appropriate treatment. Some individuals may experience long periods of remission, but the condition can potentially return.

Can diet cure my psoriasis?

No single diet can cure psoriasis, but certain dietary changes may help reduce inflammation and improve symptoms. Anti-inflammatory diets, weight loss in overweight patients, and avoiding alcohol may be beneficial as adjunct treatments.

Is it safe to exercise with psoriasis?

Exercise is generally beneficial for psoriasis patients and may help reduce inflammation and stress. However, patients should avoid activities that cause excessive sweating or skin friction, shower promptly after exercise, and moisturize well.

Can stress really trigger psoriasis flares?

Yes, psychological stress is a well-documented trigger for psoriasis flares. Stress management techniques, counseling, and relaxation methods can be important components of comprehensive psoriasis management.

Support and resources

International organizations:
– World Health Organization (WHO): who.int
– National Psoriasis Foundation: psoriasis.org
– International Federation of Psoriasis Associations (IFPA): ifpa-pso.com
– European Academy of Dermatology and Venereology (EADV): eadv.org
– Global Psoriasis Atlas: globalpsoriatlas.org
– Psoriasis Association (UK): psoriasis-association.org.uk

Related conditions

Psoriatic arthritis – Joint inflammation affecting up to 30% of psoriasis patients
Atopic dermatitis – Another chronic inflammatory skin condition with different underlying mechanisms
Seborrheic dermatitis – Inflammatory skin condition that may be confused with scalp psoriasis
Inflammatory bowel disease – Autoimmune condition with increased prevalence in psoriasis patients
Cardiovascular disease – Increased risk due to chronic systemic inflammation in psoriasis

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.